ECSP13012535A - HETEROCYCLIC COMPOUND AND ITS USES - Google Patents
HETEROCYCLIC COMPOUND AND ITS USESInfo
- Publication number
- ECSP13012535A ECSP13012535A ECSP13012535A ECSP13012535A EC SP13012535 A ECSP13012535 A EC SP13012535A EC SP13012535 A ECSP13012535 A EC SP13012535A EC SP13012535 A ECSP13012535 A EC SP13012535A
- Authority
- EC
- Ecuador
- Prior art keywords
- heterocyclic compound
- activity
- secretase
- superior
- symbol
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona un derivado heterociclo que tiene una actividad inhibidora de la producción de amiloide superior y/o una actividad de modulación de -secretasa superior, y el uso del mismo. Un compuesto representado por la fórmula (I):donde cada símbolo es como se define en la presente memoria descriptiva, o una sal del mismo.The present invention provides a heterocycle derivative that has an inhibitory activity of the production of higher amyloid and / or a modulation activity of -secretase superior, and the use thereof. A compound represented by the formula (I): where each symbol is as defined herein, or a salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010197064 | 2010-09-02 | ||
| JP2011143548 | 2011-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13012535A true ECSP13012535A (en) | 2013-06-28 |
Family
ID=45094181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13012535 ECSP13012535A (en) | 2010-09-02 | 2013-03-28 | HETEROCYCLIC COMPOUND AND ITS USES |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8901309B2 (en) |
| EP (1) | EP2611805A1 (en) |
| JP (1) | JP5871909B2 (en) |
| KR (1) | KR20130139895A (en) |
| CN (1) | CN103249733A (en) |
| AR (1) | AR082865A1 (en) |
| AU (1) | AU2011296887A1 (en) |
| BR (1) | BR112013004746A2 (en) |
| CA (1) | CA2809779A1 (en) |
| CL (1) | CL2013000575A1 (en) |
| DO (1) | DOP2013000051A (en) |
| EA (1) | EA201390333A1 (en) |
| EC (1) | ECSP13012535A (en) |
| MA (1) | MA34556B1 (en) |
| MX (1) | MX2013002511A (en) |
| PE (1) | PE20131305A1 (en) |
| PH (1) | PH12013500403A1 (en) |
| SG (1) | SG187917A1 (en) |
| TW (1) | TW201213327A (en) |
| UY (1) | UY33586A (en) |
| WO (1) | WO2012029991A1 (en) |
| ZA (1) | ZA201301929B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2455380A4 (en) * | 2009-07-13 | 2012-11-28 | Takeda Pharmaceutical | Heterocyclic compound and its use |
| BR112013004746A2 (en) * | 2010-09-02 | 2016-06-07 | Takeda Pharmaceutical | "compound, medicament, beta-amyloid production inhibitor, gamma secretase modulator, methods for inhibiting beta-amyloid production, for modulating gamma secretase, and for preventing or treating mild or alzheimer's cognitive impairment, and, use of compost. " |
| EP2687528A1 (en) * | 2012-07-17 | 2014-01-22 | Ares Trading S.A. | Fused triazole derivatives as gamma secretase modulators |
| RU2563254C2 (en) * | 2013-07-08 | 2015-09-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Method of obtaining derivatives of 7-(hetero)aryl-4,5,6,7-tetrahydro[1,2,3]triazolo[1,5-a]pyridine |
| JP7000160B2 (en) * | 2015-05-12 | 2022-01-19 | エフ エム シー コーポレーション | Aryl substituted bicyclic compounds as herbicides |
| CA3075892C (en) * | 2017-09-14 | 2024-01-23 | Daiichi Sankyo Company, Limited | Heterocyclic compounds for the treatment and/or prevention of inflammatory diseases |
| US11603440B2 (en) * | 2019-09-12 | 2023-03-14 | Dupont Electronics, Inc. | Polyimide films and electronic devices |
| WO2023114456A1 (en) * | 2021-12-17 | 2023-06-22 | Athira Pharma, Inc. | Uses of bicyclic compounds for the treatment of diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6525044B2 (en) | 2000-02-17 | 2003-02-25 | Bristol-Myers Squibb Company | Succinoylamino carbocycles and heterocycles as inhibitors of a-β protein production |
| JP4847868B2 (en) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | Compounds and their use in the regulation of amyloid beta |
| AU2004282201A1 (en) * | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| MY149038A (en) | 2004-05-26 | 2013-07-15 | Eisai R&D Man Co Ltd | Cinnamide compound |
| CA2580119A1 (en) | 2004-10-26 | 2006-05-04 | Eisai R & D Management Co., Ltd. | Amorphous object of cinnamide compound |
| CA2636946A1 (en) | 2006-01-11 | 2007-07-19 | Merck And Co., Inc. | Fused triazole tachykinin receptor antagonists |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| AR059955A1 (en) * | 2006-03-09 | 2008-05-14 | Eisai R&D Man Co Ltd | NON-PEPTIDIC POLYCLY COMPOUNDS, MEDICINES CONTAINING THEM, AND USES TO PREVENT OR TREAT DISEASES CAUSED BY THE PRODUCTION OF BETA AMYLOID |
| TW200808800A (en) | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
| EP2119719A1 (en) | 2006-12-26 | 2009-11-18 | Daiichi Sankyo Company, Limited | Thiazepine derivative |
| WO2008077649A1 (en) | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infectons |
| JP2010518080A (en) | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Remedy |
| US8450343B2 (en) | 2007-12-06 | 2013-05-28 | Xianhai Huang | Gamma secretase modulators |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| JP2010197064A (en) | 2009-02-23 | 2010-09-09 | Chugoku Electric Power Co Inc:The | Device for measuring position just below |
| JP2012051806A (en) * | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | Imidazolylpyrazine derivative |
| WO2010098487A1 (en) | 2009-02-26 | 2010-09-02 | Eisai R&D Management Co., Ltd. | Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors |
| JP2012051807A (en) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | Arylimidazole compound |
| WO2011002067A1 (en) | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | Heterocyclic compound and use thereof |
| EP2455380A4 (en) * | 2009-07-13 | 2012-11-28 | Takeda Pharmaceutical | Heterocyclic compound and its use |
| JP2012532912A (en) | 2009-07-15 | 2012-12-20 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | Substituted triazole and imidazole derivatives as gamma secretase modulators |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (en) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | Compounds for the reduction of β-amyloid production |
| WO2011016559A1 (en) | 2009-08-07 | 2011-02-10 | 武田薬品工業株式会社 | Heterocyclic compound and use thereof |
| JP2011143548A (en) | 2010-01-12 | 2011-07-28 | Panasonic Corp | Screen printing machine and screen printing method |
| BR112012017310A2 (en) | 2010-01-15 | 2016-04-19 | Janssen Pharmaceuticals Inc | substituted triazole derivatives as gamma secretase modulators |
| BR112013004746A2 (en) * | 2010-09-02 | 2016-06-07 | Takeda Pharmaceutical | "compound, medicament, beta-amyloid production inhibitor, gamma secretase modulator, methods for inhibiting beta-amyloid production, for modulating gamma secretase, and for preventing or treating mild or alzheimer's cognitive impairment, and, use of compost. " |
-
2011
- 2011-09-01 BR BR112013004746A patent/BR112013004746A2/en not_active IP Right Cessation
- 2011-09-01 UY UY0001033586A patent/UY33586A/en unknown
- 2011-09-01 US US13/819,239 patent/US8901309B2/en not_active Expired - Fee Related
- 2011-09-01 EP EP11791058.8A patent/EP2611805A1/en not_active Withdrawn
- 2011-09-01 CA CA2809779A patent/CA2809779A1/en not_active Abandoned
- 2011-09-01 AR ARP110103195A patent/AR082865A1/en unknown
- 2011-09-01 KR KR1020137008170A patent/KR20130139895A/en not_active Withdrawn
- 2011-09-01 US US13/223,455 patent/US8822699B2/en not_active Expired - Fee Related
- 2011-09-01 SG SG2013012604A patent/SG187917A1/en unknown
- 2011-09-01 PH PH1/2013/500403A patent/PH12013500403A1/en unknown
- 2011-09-01 AU AU2011296887A patent/AU2011296887A1/en not_active Abandoned
- 2011-09-01 MA MA35785A patent/MA34556B1/en unknown
- 2011-09-01 PE PE2013000360A patent/PE20131305A1/en not_active Application Discontinuation
- 2011-09-01 TW TW100131443A patent/TW201213327A/en unknown
- 2011-09-01 MX MX2013002511A patent/MX2013002511A/en not_active Application Discontinuation
- 2011-09-01 EA EA201390333A patent/EA201390333A1/en unknown
- 2011-09-01 JP JP2013510386A patent/JP5871909B2/en not_active Expired - Fee Related
- 2011-09-01 CN CN2011800518621A patent/CN103249733A/en active Pending
- 2011-09-01 WO PCT/JP2011/070419 patent/WO2012029991A1/en not_active Ceased
-
2013
- 2013-02-28 CL CL2013000575A patent/CL2013000575A1/en unknown
- 2013-03-01 DO DO2013000051A patent/DOP2013000051A/en unknown
- 2013-03-14 ZA ZA2013/01929A patent/ZA201301929B/en unknown
- 2013-03-28 EC ECSP13012535 patent/ECSP13012535A/en unknown
-
2014
- 2014-08-08 US US14/454,993 patent/US20140350260A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140350260A1 (en) | 2014-11-27 |
| US8822699B2 (en) | 2014-09-02 |
| CN103249733A (en) | 2013-08-14 |
| AU2011296887A1 (en) | 2013-04-11 |
| MX2013002511A (en) | 2013-07-29 |
| CL2013000575A1 (en) | 2013-08-23 |
| PE20131305A1 (en) | 2013-10-31 |
| WO2012029991A1 (en) | 2012-03-08 |
| AR082865A1 (en) | 2013-01-16 |
| DOP2013000051A (en) | 2013-04-30 |
| JP5871909B2 (en) | 2016-03-01 |
| UY33586A (en) | 2012-03-30 |
| TW201213327A (en) | 2012-04-01 |
| JP2013536798A (en) | 2013-09-26 |
| BR112013004746A2 (en) | 2016-06-07 |
| SG187917A1 (en) | 2013-04-30 |
| ZA201301929B (en) | 2013-11-27 |
| KR20130139895A (en) | 2013-12-23 |
| MA34556B1 (en) | 2013-09-02 |
| EA201390333A1 (en) | 2013-08-30 |
| US8901309B2 (en) | 2014-12-02 |
| US20130178497A1 (en) | 2013-07-11 |
| US20120059030A1 (en) | 2012-03-08 |
| CA2809779A1 (en) | 2012-03-08 |
| EP2611805A1 (en) | 2013-07-10 |
| PH12013500403A1 (en) | 2013-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP13012535A (en) | HETEROCYCLIC COMPOUND AND ITS USES | |
| UY36199A (en) | HETEROCYCLIC COMPOUND | |
| CR20150509A (en) | USEFUL NAFTIRIDINE DERIVATIVES AS ANTAGONISTS OF THE ALFA-V-BETA-6 INTEGRINE | |
| MX368392B (en) | FUSED HETEROCYCLIC COMPOUND. | |
| UY36489A (en) | USE OF PICOLINAMIDE COMPOUNDS WITH FUINGICIDE ACTIVITY | |
| CU24408B1 (en) | DIHYDROISOQUINOLINONA SUBSTITUTED COMPOUNDS | |
| MX2016003199A (en) | AZAPIRIDONE COMPOUNDS AND USES OF THE SAME. | |
| UY33943A (en) | SCIROCYCLIC DERIVATIVES OF ISOXAZOLINE AS ANTIPARASITARY AGENTS. | |
| BR112016014020A8 (en) | tetrahydropyridopyrazines modulators of gpr6. | |
| MX372736B (en) | AZAQUINAZOLINE INHIBITORS OF ATYPICAL PROTEIN KINASE C. | |
| MX2013006113A (en) | Bicyclic compound. | |
| CO2017001178A2 (en) | Derivative of pyridone having a tetrahydropyranyl methyl group | |
| BR112017013062A2 (en) | macrocyclic picolinamide compounds with fungicidal activity. | |
| BR112016006076A2 (en) | macrocyclic picolinamide compounds with fungicidal activity | |
| CO2019012125A2 (en) | Ip6k inhibitors | |
| MX2017002312A (en) | Heterobicyclic compounds and their use for the treatment of tuberculosis. | |
| ECSP17010238A (en) | NOVELTY PYRIMIDINE COMPOUNDS REPLACED | |
| UY36263A (en) | TIAZIN-2-AMINA COMPOUNDS FUSED WITH CYCLOPROPYL AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | |
| CO2017001506A2 (en) | Novel substituted pyrimidine compounds | |
| MX2016003892A (en) | Use of substituted dihydro-oxindolyl sulfonamides, or the salts thereof, for increasing the stress tolerance of plants. | |
| BR112015029348A2 (en) | bace inhibitors | |
| CO6491037A2 (en) | DERIVATIVES OF PIRAZINOOXAZEPINA | |
| CR20140495A (en) | 5-AMINO [1,4] THIAZINES AS INHIBITORS OF BACE1 | |
| CL2017001467A1 (en) | Dihydropyrimidin - 2 - one compounds and their medical uses | |
| BR112016028022A2 (en) | sulfonamide compounds and their uses as stat5 inhibitors |